WEBVTT

00:00:01.555 --> 00:00:05.532
Generate: Biomedicines

00:00:05.760 --> 00:00:09.760
[GB-0895], [TSLP]
GB-0895 is a type of medicine called a monoclonal

00:00:09.840 --> 00:00:14.320
antibody which has been designed to block a protein in the body called TSLP.

00:00:15.040 --> 00:00:19.360
TSLP can be released by cells in your body when they interact with items like

00:00:19.440 --> 00:00:21.760
allergens, irritants or infections.

00:00:23.800 --> 00:00:27.520
For patients with asthma, when there is too much TSLP that has been

00:00:27.600 --> 00:00:30.880
[Symptopms]
released into your body, It triggers an inflammation response,

00:00:31.120 --> 00:00:34.400
which can make your airways swollen and narrow, which causes shortness

00:00:34.560 --> 00:00:36.720
of breath, coughing, and wheezing.

00:00:37.930 --> 00:00:38.711
GB-0895, Affinity, Half-life, Binding target

00:00:38.711 --> 00:00:42.080
GB0895 works by attaching itself to TSLP.

00:00:42.640 --> 00:00:47.680
When it attaches, TSLP is no longer able to trigger an inflammation response.

00:00:49.000 --> 00:00:52.800
GB0895 is also unique in being investigated

00:00:52.960 --> 00:00:58.000
further because it may be able to block TSLP more strongly directly in the lungs,

00:00:58.320 --> 00:01:02.880
and has also been shown in early studies to last last longer in the body before it breaks down. [Lasts longer in the body]

00:01:04.594 --> 00:01:05.968
The goal: fewer injections, easier treatment, fewer hospital visits

00:01:05.992 --> 00:01:07.840
This would mean fewer injections, which allows patients to keep up

00:01:07.920 --> 00:01:11.294
with treatment more easily, which hopefully would lead to fewer

00:01:11.360 --> 00:01:13.680
asthma flare-ups and hospital visits.